CDKN2A and neoplasm: Interestingly, we found that CDKN2A expression was significantly associated with tumor immune-related pathways such as the TNFA signaling pathway via NFKB, IFN-α response, IFN-γ response, allograft rejection pathway and inflammatory response, especially in BLCA, CESC, MESO, OV, TGCT and THCA (Figure 3).